Search Results - First Line

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia. by Hou, Jing-Zhou, Choksi, Rushir, Maglinte, Gregory A., Wang, Xiaoliang, Rui, Pinyao, Suryavanshi, Manasi, Allendorf, Daniel, Patel, Taral, Dadla, Ali, Fontaine, Annette, Jonglertham, Pornchai, Aton, Lindsay, Hagan, Melissa, Morere, Lisa, Scott, Jeffrey, Williams, Rhys, Ermann, Daniel A.

View this record in EBSCOhost

Camrelizumab plus rivoceranib as first-line maintenance therapy after camrelizumab-chemo induction in advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase... by Song, Na, Qu, Jinglei, Chen, Ying, Li, Danni, Qu, Xiujuan

View this record in EBSCOhost

Efficacy and safety of first-line modified docetaxel, cisplatin, and fluorouracil (mDCF) in advanced esophageal cancer: A retrospective study from Viet Nam. by Can, Hong Thi Anh, Nguyen Thi Huong, Giang, Tran, Dung Xuan, Hoang, Giap Ngoc

View this record in EBSCOhost

Comparative effectiveness of first-line ribociclib plus aromatase inhibitor versus palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer: A global real-world e... by Biswas, Shankar, Srivastava, Yashasvi, Hamadttu, Ayman

View this record in EBSCOhost

Hallmarks based stratification of locally advanced GBC according to response to first-line chemotherapy in advanced gallbladder cancer (GBC). by Agrawal, Sushma, M., Raghunath, Gupta, Ojas, Varghese, Linu, Gowda, Pooja, S. P., Sreekanth, Saha, Prabir, Periyasamy, Giridharan, Goswami, Hitesh, Rishi, Kshitij, Veldore, Vidya H.

View this record in EBSCOhost

Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis. by Biswas, Shankar, Srivastava, Yashasvi, Falodia, Rahul, Hamadttu, Ayman

View this record in EBSCOhost

Real-world efficacy of cabozantinib in combination with pemetrexed and carboplatin followed by pemetrexed-cabozantinib maintenance as first-line therapy for metastatic KRAS-mutant... by Agarwala, Vivek, Chandrakanth, M.V., Sharma, Amit, Dasgupta, Anish, Roy, Minakshi, Sen, Nibedita, Mandal, Kaustav, Basu, Moinak, Raj, Aryan, Auddya, Paramita, Nayak, Himadri

View this record in EBSCOhost

Treatment outcomes with first-line EGFR tyrosine kinase inhibitors in Vietnamese metastatic NSCLC patients harboring compound EGFR mutations. by Ngoc, Hoang Bao, Do, Kien Hung, Linh, Do Mai, Nguyen, Van Tai

View this record in EBSCOhost

Real-world outcomes of first-line afatinib in advanced non–small cell lung cancer patients with uncommon EGFR mutations at Vietnam National Cancer Hospital. by Nguyen, Anh Tuan

View this record in EBSCOhost

Real-world efficacy and safety of first-line durvalumab combined with platinum–etoposide in extensive-stage small cell lung cancer: A single-center experience in Vietnam. by Do, Kien Hung, Nguyen, Van Tai, Nguyen, Phuong, Nguyen, Thi Nhu Hoa, Tran, Hau Thi, Dao, The Minh, Nguyen, Tuan Anh, Ngoc, Hoang Bao, Hang, Doan Nguyet

View this record in EBSCOhost

Impact of smoking status on the efficacy of first-line immune checkpoint inhibitors in Asian patients with advanced non-small cell lung cancer: A meta-analysis. by Mateen, Raghda, Anand, Aditya, Verma, Nikhil, Narula, Harshit

View this record in EBSCOhost

Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with adebrelimab plus chemotherapy (CLOG2402-ADAPT): A mult... by Zhang, Lingyun, Zhang, Xiuna, Piao, Jinhua, Wang, Zhenghua, Tian, Hong, Liu, Yunpeng, Qu, Xiujuan

View this record in EBSCOhost

An oral anlotinib-capecitabine regimen plus penpulimab as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, phase 2 clinica... by Xu, Cheng, Qu, Song, Liu, Zhigang, Yang, Kunyu, Huang, Ying, Guo, Ling, Luo, Dong-Hua, Tang, Ling-Long, Cai, Qingqing, Xia, Yi, Zhou, Guan-Qun, Zhang, Yuan, Su, Fang, Wang, Zhiqiang, Hong, Xiaohua, Li, Jibin, Li-Zhi, Liu, Tian, Li, Li, Haojiang, Ma, Jun

View this record in EBSCOhost

First-line maintenance olaparib in a low–body mass index Asian population with advanced ovarian cancer: Real-world outcomes from a Vietnamese cohort. by Nguyen, Long Thanh, Huyen, Phung Thi

View this record in EBSCOhost

Comparative efficacy and safety of first-line maintenance therapies in advanced ovarian cancer: A biomarker-stratified Bayesian network meta-analysis of 16 phase 3 trials. by Falodia, Rahul, Biswas, Shankar

View this record in EBSCOhost

Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial. by Qiu, Haifeng, Guo, Ruixia

View this record in EBSCOhost

Comparative efficacy and safety of first-line systemic combinations for advanced urothelial carcinoma: A Bayesian network meta-analysis. by Falodia, Rahul, Biswas, Shankar, Srivastava, Yashasvi

View this record in EBSCOhost

Comparative effectiveness of first-line pembrolizumab plus chemotherapy, nivolumab plus chemotherapy, and nivolumab plus ipilimumab in metastatic esophageal squamous cell carcinoma... by Biswas, Shankar, Srivastava, Yashasvi, Falodia, Rahul, Hamadttu, Ayman

View this record in EBSCOhost

Comparative real-world outcomes of durvalumab plus gemcitabine/cisplatin versus pembrolizumab plus gemcitabine/cisplatin as first-line therapy for advanced biliary tract cancer. by Biswas, Shankar, Srivastava, Yashasvi, Hamadttu, Ayman

View this record in EBSCOhost

Real-world comparison of cabozantinib versus regorafenib as second-line therapy for advanced hepatocellular carcinoma after first-line immune checkpoint inhibitors: A propensity sc... by Biswas, Shankar, Srivastava, Yashasvi, Hamadttu, Ayman

View this record in EBSCOhost